• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

监管影响分析:ANVISA 更好监管的新工具。

Regulatory Impact Analysis: a new tool for better regulation at ANVISA.

机构信息

Agência Nacional de Vigilância Sanitária, Brasília, DF, Brasil. fl

出版信息

Rev Saude Publica. 2011 Aug;45(4):802-5. doi: 10.1590/s0034-89102011000400023.

DOI:10.1590/s0034-89102011000400023
PMID:21779641
Abstract

Regulatory Impact Analysis, which is recommended to regulatory departments, aims to improve regulatory quality by providing information about the costs and benefits of regulation as well as solutions to current issues to enhance the decision-making process. This article discusses the importance of Regulatory Impact Analysis in the context of the National Agency for Sanitary Surveillance performance as well as the agency's current phase of regulation improvement and strengthening. Also, the main definitions related to the regulatory field as well as some international case experiences are presented.

摘要

监管影响分析(Regulatory Impact Analysis),推荐给监管部门,旨在通过提供监管成本和收益信息以及解决当前问题的方案,来提高监管质量,从而增强决策过程。本文讨论了监管影响分析在国家卫生监督局表现方面的重要性,以及该机构在监管改进和加强方面的当前阶段。此外,还介绍了与监管领域相关的主要定义以及一些国际案例经验。

相似文献

1
Regulatory Impact Analysis: a new tool for better regulation at ANVISA.监管影响分析:ANVISA 更好监管的新工具。
Rev Saude Publica. 2011 Aug;45(4):802-5. doi: 10.1590/s0034-89102011000400023.
2
Institutional change and political decision-making in the creation of the Brazilian National Health Surveillance Agency.巴西国家卫生监督局创建过程中的制度变革与政治决策
Cad Saude Publica. 2007 Jun;23(6):1373-82. doi: 10.1590/s0102-311x2007000600012.
3
[The National Health Surveillance Agency, ANVISA, and clinical research in Brazil].[巴西国家卫生监督局(ANVISA)与巴西的临床研究]
Rev Assoc Med Bras (1992). 2006 Jan-Feb;52(1):60-2. doi: 10.1590/s0104-42302006000100025. Epub 2006 Apr 10.
4
A Baseline Analysis of Regulatory Review Timelines for ANVISA: 2013-2016.巴西国家卫生监督局(ANVISA)监管审查时间表的基线分析:2013 - 2016年
Ther Innov Regul Sci. 2020 Nov;54(6):1428-1435. doi: 10.1007/s43441-020-00169-5. Epub 2020 Jun 9.
5
[Sanitary regulation as part of health policy in Brazil: gaps and challenges].[巴西卫生政策中的卫生法规:差距与挑战]
Rev Panam Salud Publica. 2016 May;39(5):226-231.
6
Quality of medicines: Deficiencies found by Brazilian Health Regulatory Agency (ANVISA) on good manufacturing practices international inspections.药品质量:巴西卫生监管局(ANVISA)在国际检查中发现的良好生产规范缺陷。
PLoS One. 2018 Aug 8;13(8):e0202084. doi: 10.1371/journal.pone.0202084. eCollection 2018.
7
Should ANVISA be permitted to reject pharmaceutical patent applications in Brazil?巴西的 ANVISA 是否应被允许拒绝药品专利申请?
Expert Opin Ther Pat. 2014 Jan;24(1):1-4. doi: 10.1517/13543776.2014.854773. Epub 2013 Nov 9.
8
A regulatory governance perspective on health technology assessment (HTA) in France: the contextual mediation of common functional pressures.法国卫生技术评估(HTA)的监管治理视角:常见功能压力的情境调解
Health Policy. 2015 Feb;119(2):137-46. doi: 10.1016/j.healthpol.2014.10.002. Epub 2014 Oct 14.
9
Understanding the administrative regulation on occupational health and trend in China.了解中国的职业健康行政法规和趋势。
J Occup Health. 2018 Mar 27;60(2):126-131. doi: 10.1539/joh.17-0229-RA. Epub 2017 Dec 28.
10
Regulatory beneficiaries and informal agency policymaking.监管受益者与非正式机构决策制定
Cornell Law Rev. 2007 Mar;92(3):397-452.